3D Systems (DDD) announced that the U.S. Food and Drug Administration has granted 510(k) clearance expanding the indications for its VSP Orthopedics virtual surgical planning and patient-specific instrumentation platform to include skeletally mature adolescents of normal bone stature, in addition to adults.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DDD:
- 3D Systems Reduces Debt with Note Exchange Agreement
- 3D Systems announces $31M equitization transaction
- 3D Systems management to meet virtually with Needham
- 3D Systems: Hold Rating Amid Mixed Financial Performance and Market Challenges
- 3D Systems price target raised to $4.75 from $4 at Cantor Fitzgerald